[The utilization and limitation of CD133 epitopes in lung cancer stem cells research].
Lung cancer is one of the most common tumor, which lacks of effective clinical treatment to lead to desirable prognosis. According to cancer stem cell hypothesis, lung cancer stem cells are considered to be responsible for carcinogenesis, development, metastasis, recurrence, invasion, resistance to chemotherapy and radiotherapy of lung cancer. In recent years, more and more institutes used glycosylated CD133 epitopes to define, isolate, purify lung cancer stem cells. However, along with deeply research, the application of CD133 epitopes in lung cancer stem cell research is questioned. The utilization and limitation of CD133 epitopes in lung cancer stem cells research for the past few years is summaried in this review.
Department of Thoracic and Cardiovascular Surgery, Xinhua Hospital, School of Medicine, Shanghai Jiaotong University, China.
Yin
Y
Chen
Hong
H
Zhong
D000071916:AC133 Antigen; D000818:Animals; D015703:Antigens, CD / Q000032:analysis*; D014408:Biomarkers, Tumor / Q000032:analysis; D000939:Epitopes / Q000032:analysis; D006023:Glycoproteins / Q000032:analysis*; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis / Q000378:metabolism*; D014411:Neoplastic Stem Cells / Q000378:metabolism*; D010455:Peptides / Q000032:analysis*; D012680:Sensitivity and Specificity; D057905:Stem Cell Research
D000071916:AC133 Antigen; D015703:Antigens, CD; D014408:Biomarkers, Tumor; D000939:Epitopes; D006023:Glycoproteins; C000606023:PROM1 protein, human; D010455:Peptides